Prognostic Value of the Systemic Inflammation Response Index in Patients with Adenocarcinoma of the Oesophagogastric Junction: A Propensity Score-Matched Analysis

Table 2

Relationship between NLR, PLR, or MLR and clinicopathological characteristics of patients with adenocarcinoma of oesophagogastric junction.

Clinical parameter	NLR				PLR				MLR
	≤1.70 (102)	>1.70 (200)	^2		≤96 (76)	>96 (226)	^2		≤0.20 (84)	>0.20 (218)	^2
Sex			14.70	<0.001			6.21	0.013			20.44	<0.001
Male	70	174			54	190			54	190
Female	32	26			22	36			30	28
Age			0.05	0.831			2.40	0.122			0.70	0.403
≤60	39	79			24	94			36	82
>60	63	121			52	132			48	136
Grade			0.61	0.737			0.66	0.720			5.63	0.060
Well	6	9			5	10			8	7
Moderately	71	135			52	154			57	149
Poorly	25	56			19	62			19	62
Tumour size			3.15	0.076			3.63	0.057			0.35	0.552
≤5 cm	77	131			59	149			60	148
>5 cm	25	69			17	77			24	70
T stage			7.00	0.072			6.15	0.104			5.66	0.130
Tis-T1	20	23			16	27			18	25
T2	15	18			11	22			9	24
T3	39	97			28	108			37	99
T4	28	62			21	69			20	70
N stage			2.20	0.533			2.50	0.476			5.62	0.132
N0	46	76			36	86			42	80
N1	22	42			14	50			18	46
N2	19	41			15	45			12	48
N3	15	41			11	45			12	44
AJCC TNM stage			7.85	0.020			7.01	0.030			7.22	0.027
I	32	35			23	44			26	41
II	30	64			27	67			28	66
III	40	101			26	115			30	111
Vascular invasion			1.23	0.267			0.78	0.376			4.18	0.041
No	94	176			70	200			80	190
Yes	8	24			6	26			4	28
SIRI			99.23	<0.001			29.16	<0.001			89.02	<0.001
≤0.68	79	37			49	67			68	48
>0.68	23	163			27	159			16	170
PLR			26.42	<0.001			—	—			22.03	<0.001
≤96	44	32			—	—			37	39
>96	58	168			—	—			47	179
NLR			—	—			26.42	<0.001			48.43	<0.001
≤1.70	—	—			44	58			54	48
>1.70	—	—			32	168			30	170
MLR			48.43	<0.001			22.03	<0.001			—	—
≤0.20	54	30			37	47			—	—
>0.20	48	170			39	179			—	—

AJCC: American Joint Committee on Cancer; SIRI: systemic inflammation response index; PLR: platelet lymphocyte ratio; NLR: neutrophil lymphocyte ratio; MLR: monocyte lymphocyte ratio.